Navigation Links
In Turkey, the Use of Targeted Therapies Will Continue to Sustain the Colorectal Cancer Drug Market

BURLINGTON, Mass., Sept. 25, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that, from 2012 to 2017, the colorectal cancer (CRC) market in Turkey will grow at an annual rate of four percent, reaching $90 million in 2017. The Emerging Markets report entitled Colorectal Cancer in Turkey finds that the rapidly growing CRC patient population, the launches of several new branded therapies, and the continued use of branded agents, in particular targeted therapies, Roche's Avastin (Altuzan in Turkey) and Merck's Erbitux, will drive growth in this market.

Between 2012 and 2017, five branded CRC therapies will launch in Turkey, namely Amgen's Vectibix (launched in Turkey in May 2013), Bayer's Stivarga, Sanofi's Zaltrap, Alchemia's HA-irinotecan and Eli Lilly's ramucirumab. As a result of current therapies being well entrenched in the market, new therapies will provide some competition to the existing agents but will not substantially diminish their patient shares—new therapies will together contribute 11 percent to the total CRC market in 2017.

The report also finds that the number of incident cases of CRC in Turkey will almost double between 2012 and 2022, mainly due to an increase in disease risk, but also because of growing and aging population.

"Turkish oncologists frequently use targeted therapies when treating their metastatic CRC patients and interviewed experts report that all of their metastatic patients undergo KRAS testing–this is more in line with the medical practice of the major markets than of some other emerging markets that we cover," said Decision Resources Analyst Natalia Reoutova, MA, MSc. "Although the drug price cuts implemented by the Turkish government have an obvious constraining effect on the market equally, they also allow the targeted agents to enjoy the comparatively high patient shares, which otherwise would be a lot lower."

The new report features extensive primary research with Turkish oncologists as well as a market outlook through 2017.

About Decision Resources
Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. K94 Discoveries, Inc. Announces Seed Financing To Advance Targeted Drug Conjugates To Treat Pancreatic And Other Cancers
2. New Drug that Delivers Targeted Radiation Minimizes Pain and May Extend Prostate Cancer Survival
3. MultiCell Technologies and Genisphere Evaluate Targeted Delivery of MCT-485, a Noncoding miRNA for the Treatment of Cancer
4. Protein Targeted For Cancer Drug Development Is Essential For Normal Heart Function
5. Emerging Targeted Therapies Offer Efficacy Advantages Over Currently Used Chemotherapies for Platinum-Resistant Advanced Ovarian Cancer
6. Advanced Prenatal Therapeutics - Using Targeted Apheresis to Treat Preeclampsia
7. Actinium Pharmaceuticals Clinical Results to be Presented at 8th International Symposium on Targeted Alpha Therapy Conference
8. MultiCell Technologies Files U.S. Patent Application for Targeted Delivery of Noncoding Micro RNAs for the Treatment of Liver Cancer
9. Algeta and Lumiphore Announce Further Expansion of Their Global Partnership for the Development of Targeted Alpha-pharmaceutical Cancer Therapeutics and Companion Diagnostics.
10. ADial Pharmaceuticals Announces Agreement With FDA For Phase III Trial Of AD04 For Alcohol Use Disorder In Patients Of Targeted Genotypes
11. KaloBios Targeted Antibacterial KB001-A to be Featured in BIO 2013 Panel Discussion of "New Defenses Against Old Enemies"
Post Your Comments:
(Date:6/24/2016)... Dublin ... of the " Global Markets for Spectroscopy Equipment" ... This report focuses on the global ... including its applications in various applications. The report deals ... three main industries: pharmaceutical and biotechnology, food and beverage, ...
(Date:6/24/2016)... 2016 The Academy of Managed Care Pharmacy ... that would allow biopharmaceutical companies to more easily share ... formulary and coverage decisions, a move that addresses the ... The recommendations address restrictions in the sharing ... drug label, a prohibition that hinders decision makers from ...
(Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016  American Respiratory ... testing company, is now able to perform sophisticated lung assessments in ... Medical Technologies , Inc. Patients are no longer ... to ndd,s EasyOne PRO ® , ARL patients like Jeanne R. ... testing done in the comfort of her own home. ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, ... Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. ... skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/25/2016)... ... 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the ... to iHire in recognition of their exemplary accomplishments in worksite health promotion. , The ... Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
(Date:6/24/2016)... Texas (PRWEB) , ... June 24, 2016 , ... ... International Conference and Scientific Sessions in Dallas that it will receive two significant ... of the grants came as PHA marked its 25th anniversary by recognizing patients, ...
Breaking Medicine News(10 mins):